A study of angiotensin–neprilysin inhibitor versus enalapril in heart failure with reduced ejection fraction in a tertiary care hospital in eastern india

Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2. The effect of angiotensin-receptor blockers (ARBs) on mortality has been inconsistent,3,4. Combined inhibition of ACE and neprilysin was associated with serious angioedema. In our study we have compared the angiotensin receptor–neprilysin inhibitor (sacubitril- valsartan) with enalapril in patients who had heart failure with a reduced ejection fraction.